We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

139 hedge funds and large institutions have $376M invested in Catalyst Pharmaceutical in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 57 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 16

21% more capital invested

Capital invested by funds: $312M → $376M (+$64.5M)

5% more funds holding

Funds holding: 133 → 139 (+6)

1.84% less ownership

Funds ownership: 65.2% → 63.36% (-1.8%)

32% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 57

75% less call options, than puts

Call options by funds: $634K | Put options by funds: $2.57M

Holders
139
Holders Change
+6
Holders Change %
+4.51%
% of All Funds
2.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
39
Reduced
57
Closed
16
Calls
$634K
Puts
$2.57M
Net Calls
-$1.94M
Net Calls Change
-$2.5M

Top Buyers

1
LSV Asset Management
LSV Asset Management
Illinois
+$14.6M
2
JP Morgan Chase
JP Morgan Chase
New York
+$4.04M
3
Wells Fargo
Wells Fargo
California
+$3.4M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.56M
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$1.48M

Top Sellers

1
State Street
State Street
Massachusetts
-$15.1M
2
Prudential Financial
Prudential Financial
New Jersey
-$4.23M
3
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$3.54M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$3.1M
5
AQR Capital Management
AQR Capital Management
Connecticut
-$2.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$2.28M -$838K -162,331 -29%
BGIM
27
Brandywine Global Investment Management
Pennsylvania
$2.01M -$22K -4,259 -1%
Two Sigma Investments
28
Two Sigma Investments
New York
$1.99M -$1.21M -235,188 -40%
Morgan Stanley
29
Morgan Stanley
New York
$1.99M +$1.31M +253,903 +277%
GCM
30
Gables Capital Management
Florida
$1.97M -$336K -65,100 -16%
WANY
31
Wealthspire Advisors (New York)
New York
$1.94M – – –
ACP
32
Acuta Capital Partners
California
$1.89M +$1.3M +251,134 +322%
AQR Capital Management
33
AQR Capital Management
Connecticut
$1.86M -$2.06M -399,455 -55%
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
$1.76M +$711K +137,826 +82%
Man Group
35
Man Group
United Kingdom
$1.76M -$301K -58,327 -16%
Millennium Management
36
Millennium Management
New York
$1.72M -$1.61M -312,637 -51%
Citigroup
37
Citigroup
New York
$1.69M -$1.95M -378,729 -56%
PC
38
Prairiewood Capital
North Dakota
$1.48M +$6.71K +1,300 +0.5%
First Trust Advisors
39
First Trust Advisors
Illinois
$1.4M -$49K -9,501 -4%
RJFSA
40
Raymond James Financial Services Advisors
Florida
$1.37M +$10.3K +1,998 +0.8%
HW
41
Hancock Whitney
Mississippi
$1.37M -$1.07K -208 -0.1%
AA
42
ALPS Advisors
Colorado
$1.25M -$265K -51,382 -19%
Swiss National Bank
43
Swiss National Bank
Switzerland
$1.25M -$39.2K -7,600 -3%
Macquarie Group
44
Macquarie Group
Australia
$1.21M +$440K +85,216 +68%
Citadel Advisors
45
Citadel Advisors
Florida
$1.19M +$844K +163,506 +376%
UBS AM
46
UBS AM
Illinois
$1.16M +$38.6K +7,474 +4%
Victory Capital Management
47
Victory Capital Management
Texas
$1.11M -$51K -9,890 -5%
Rafferty Asset Management
48
Rafferty Asset Management
New York
$1.1M -$1.26M -243,632 -56%
Bank of America
49
Bank of America
North Carolina
$1.06M -$106K -20,601 -10%
Los Angeles Capital Management
50
Los Angeles Capital Management
California
$999K +$897K +173,785 New
1
2
3 4 5

CPRX Hedge Fund Activity: Q2 2021 in Review

139 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2021, worth a combined $376M — up 21% from $312M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CPRX positions and 16 closed out — a net gain of 7 holders — while 39 added to existing stakes and 57 trimmed.

The largest buyer was LSV Asset Management, adding an estimated $14.6M. The largest seller was State Street, cutting an estimated $15.1M.

  • 139 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2021, up from 133 in Q1 2021.
  • Funds reported $376M of Catalyst Pharmaceutical stock for Q2 2021, up 21% quarter-over-quarter.
  • 23 funds opened new Catalyst Pharmaceutical positions in Q2 2021 and 16 closed out, a net change of +7 holders.
  • The largest Catalyst Pharmaceutical buyer in Q2 2021 was LSV Asset Management, an estimated $14.6M added.
  • The largest Catalyst Pharmaceutical seller in Q2 2021 was State Street, an estimated $15.1M sold.

Based on aggregated 13F filings for Q2 2021.